Zobrazeno 1 - 10 of 31 pro vyhledávání: '"CHRISTOF M. KAZDA"'
1
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
Autor: Juliana M. Bue-Valleskey, Christof M. Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt, Juan P. Frias
Publikováno v: Diabetes Care. 46:1060-1067
OBJECTIVE Basal insulin Fc (BIF) (insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::554f271b1679eb8ceb0cb386d844a4f3
https://doi.org/10.2337/dc22-2396
Zobrazit plný text záznamu
2
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes
Autor: Christof M. Kazda, Juliana M. Bue-Valleskey, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Paula Wullenweber, Axel Haupt, Dominik Dahl
Publikováno v: Diabetes Care. 46:1052-1059
OBJECTIVE Basal Insulin Fc (BIF; insulin efsitora alfa; LY3209590), a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for once-weekly basal insulin administration. This phase 2 study assessed safe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b09912fe9e31ff8d441e60a36156d404
https://doi.org/10.2337/dc22-2395
Zobrazit plný text záznamu
5
Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus H umalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study
Autor: Christof M. Kazda, Jennifer Leohr, Thomas A. Hardy, Mary Anne Dellva, Christoph Kapitza, Mark Matzopoulos, Mei Teng Loh, Rong Liu, Shobha Reddy, Oliver Klein
Publikováno v: Diabetes, Obesity and Metabolism. 24:187-195
AIMS To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes mellitus (T2D). MATERIALS AND METHODS Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb4eef7c35470da7c8843e3c1b823e41
https://doi.org/10.1111/dom.14561
Zobrazit plný text záznamu
6
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study
Autor: Mary Anne Dellva, Jennifer Leohr, Shobha Reddy, Christof M. Kazda, Thomas Hardy, Mei Teng Loh, Rong Liu, Leona Plum-Mörschel
Publikováno v: Diabetes, Obesity and Metabolism. 24:196-203
Aim This study compared the pharmacokinetics (PK), glucodynamics (GD), and tolerability following single and multiple daily subcutaneous (SC) doses of ultra rapid lispro (URLi) and Humalog in patients with type 1 diabetes mellitus (T1D). Materials an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23d6f588ea561ceca2ec7d833c92157
https://doi.org/10.1111/dom.14563
Zobrazit plný text záznamu
7
215-OR: Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily (QD) Insulin Degludec (DEG) in Insulin-Naïve Patients with Type 2 Diabetes (T2D)
Autor: JULIANA M. BUE-VALLESKEY, CHRISTOF M. KAZDA, CHENCHEN MA, JENNY CHIEN, QIANYI ZHANG, EMMANUEL CHIGUTSA, WILLIAM LANDSCHULZ, JENNIFER SWAN, AXEL HAUPT, JUAN PABLO FRIAS
Publikováno v: Diabetes. 71
Basal Insulin Fc (BIF; LY3209590) , a fusion protein combining a novel single-chain insulin variant with a human IgG Fc domain, is designed for QW administration. This randomized, parallel, open-label Ph2 study assessed safety and efficacy of BIF vs.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd81c598289c43c859631cd2b112b458
https://doi.org/10.2337/db22-215-or
Zobrazit plný text záznamu
8
192-OR: Glycemic Control with Once-Weekly Basal Insulin Fc (BIF) in Persons with Type 2 Diabetes Mellitus (T2DM) Using Continuous Glucose Monitoring (CGM) in a Phase 2 Study
Autor: Paula Wullenweber, William H. Landschulz, Qianyi Zhang, Christof M. Kazda, Juan P. Frias, Axel Haupt, Emmanuel Chigutsa, Jenny Y. Chien
Publikováno v: Diabetes. 70
Basal insulin Fc (BIF; LY3209590) is a novel, once-weekly, long-acting IgG Fc-fusion protein assessed for the treatment of diabetes mellitus. A 32-week study evaluating the safety and efficacy of BIF vs. degludec in persons with T2DM previously treat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::240ed3bfb652536118746fbca6890b14
https://doi.org/10.2337/db21-192-or
Zobrazit plný text záznamu
10
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist
Autor: Naga Chalasani, Thomas Hardy, Suman Duvvuru, Sudha S. Shankar, Anthony Akkari, Xiaotian Michelle Zhang, Sreekumar G. Pillai, Christof M. Kazda, Mark A. Deeg, Chakib Battioui, Pallav Bhatnagar, Wendra M. Foster, Cristina B. Guzman
Publikováno v: Hepatology Communications. 2:561-570
LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29415cd08f7a70309a76379dfe48093e
https://doi.org/10.1002/hep4.1171
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje